Minocycline: far beyond an antibiotic
Tóm tắt
Minocycline is a second‐generation, semi‐synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properties against both gram‐positive and gram‐negative bacteria. It is mainly used in the treatment of acne vulgaris and some sexually transmitted diseases. Recently, it has been reported that tetracyclines can exert a variety of biological actions that are independent of their anti‐microbial activity, including anti‐inflammatory and anti‐apoptotic activities, and inhibition of proteolysis, angiogenesis and tumour metastasis. These findings specifically concern to minocycline as it has recently been found to have multiple non‐antibiotic biological effects that are beneficial in experimental models of various diseases with an inflammatory basis, including dermatitis, periodontitis, atherosclerosis and autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. Of note, minocycline has also emerged as the most effective tetracycline derivative at providing neuroprotection. This effect has been confirmed in experimental models of ischaemia, traumatic brain injury and neuropathic pain, and of several neurodegenerative conditions including
Từ khóa
Tài liệu tham khảo
Aronson AL, 1980, Pharmacotherapeutics of the newer tetracyclines, J Am Vet Med Assoc, 176, 1061
Arsenis C, 1992, Tetracyclines (TETs) inhibit the synthesis and/or activity of cartilage proteinases in vivo and in vitro, Matrix Suppl, 1, 314
Esterly NB, 1984, Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy, Arch Dermatol, 120, 1308, 10.1001/archderm.1984.01650460048018
Golub L, 1992, Tetracyclines (TCs) inhibit matrix metalloproteinases (MMPs): in vivo effects in arthritic and diabetic rats and new in vitro studies, Matrix Suppl, 1, 315
Greenwald R, 1993, Tetracyclines in arthritis, J Rheumatol, 20, 1990
Greenwald RA, 1987, Tetracyclines inhibit human synovial collagenase in vivo and in vitro, J Rheumatol, 14, 28
Greenwald RA, 1992, Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage, J Rheumatol, 19, 927
Holman BL, 1975, Time course of 99mTc(Sn)‐tetracycline uptake in experimental acute myocardial infarction, J Nucl Med, 16, 1144
Holman BL, 1973, Detection and localization of experimental myocardial infarction with 99m Tc‐tetracycline, J Nucl Med, 14, 595
Koistinaho J, 1997, Altered gene expression in brain ischemia, Neuroreport, 8, i
Stone M, 2003, Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity, J Rheumatol, 30, 2112
Zernicke RF, 1997, Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis, J Rheumatol, 24, 1324
Zhang J, 1994, Changes of monoamines, purines and amino acids in rat striatum as measured by intercerebral microdialysis during ischemia/reperfusion, Chin Med Sci J, 9, 225